Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment

Saved in:
Bibliographic Details
Published in:Blood 2005-06, Vol.105 (12), p.4893-4894
Main Authors: Schultheis, Beate, Szydlo, Richard, Mahon, François X., Apperley, Jane F., Melo, Junia V.
Format: Article
Language:English
Subjects:
Antigens, CD34 - biosynthesis
Antineoplastic Agents - therapeutic use
Benzamides
Cell Proliferation
Cryopreservation
Dose-Response Relationship, Drug
Flow Cytometry
Humans
Imatinib Mesylate
Immunomagnetic Separation - methods
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology
Leukocytes, Mononuclear - immunology
Phosphotyrosine - chemistry
Pilot Projects
Piperazines - therapeutic use
Pyrimidines - therapeutic use
Remission Induction
Reproducibility of Results
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2005-01-0210